Neurology Treatment Denied by Insurance: Appeal

Neurological conditions — ranging from chronic migraine to multiple sclerosis to epilepsy — affect more than 100 million Americans and represent some of the most common and costly reasons for insurance claim denials. Whether it's a migraine biologic, an MS disease-modifying therapy, an epilepsy device, or a neuropsychological evaluation, insurance denials for neurology care are frustratingly common. This guide covers the most frequent neurology denial scenarios and how to appeal each effectively.

Common Neurology Denial Scenarios

Migraine Biologics (CGRP Inhibitors)

The anti-CGRP biologic class — including erenumab (Aimovig), fremanezumab (Ajovy), galcanezumab (Emgality), and eptinezumab (Vyepti) — represents the first class of drugs specifically developed for migraine prevention. Denials for these agents typically cite:

• Inadequate step therapy: Most payers require failure of 2–4 preventive medications from different drug classes (propranolol/metoprolol, topiramate/valproate, amitriptyline/nortriptyline, verapamil) before approving a CGRP inhibitor. Document each agent tried with dose, duration (at least 6–8 weeks at therapeutic dose), and reason for discontinuation (lack of efficacy, intolerance, or contraindication).

• Migraine frequency not documented: Payers require documentation of episodic migraine (4–14 headache days per month) or chronic migraine (15+ headache days per month, at least 8 of which are migraines). A headache diary — documenting daily headache presence, severity (numeric rating scale), associated features (nausea, photophobia, phonophobia), and whether triptans were taken — is essential evidence.

• Cite AHS/AAN guidelines: The American Headache Society (AHS) and American Academy of Neurology (AAN) endorse CGRP inhibitors for patients with episodic or chronic migraine who have failed 2+ preventive therapies. Include this in your appeal.

Multiple Sclerosis Disease-Modifying Therapies

MS DMTs — including interferon betas, glatiramer acetate, natalizumab (Tysabri), ocrelizumab (Ocrevus), ofatumumab (Kesimpta), siponimod (Mayzent), and many others — face denials for:

• Step therapy requiring less effective agents first: Payers may require that patients try injectable platform therapies (interferons, glatiramer) before high-efficacy agents (natalizumab, ocrelizumab). The American Academy of Neurology's MS management guidelines support early high-efficacy therapy for active or aggressive MS — cite this when the neurologist believes a high-efficacy agent is appropriate first-line.

• Relapsing vs. progressive MS type disputes: Some DMTs are approved only for relapsing forms of MS; others (ocrelizumab) are approved for primary progressive MS. Ensure the diagnosis documentation (MRI with lesions, clinical history, CSF oligoclonal bands) clearly establishes the MS phenotype.

• MRI evidence of activity: Document gadolinium-enhancing lesions or new T2 lesions on MRI — these are objective markers of active disease that support the need for DMT.

Neuropsychological Testing

Neuropsychological evaluations — comprehensive cognitive testing lasting 6–8 hours — are frequently denied as "not medically necessary." Key arguments:

• Document the clinical indication: post-stroke cognitive assessment, ADHD evaluation when medication decisions depend on diagnosis, dementia workup, traumatic brain injury assessment, pre-surgical epilepsy evaluation, or learning disability assessment in children.
• Neuropsychological testing cannot be replaced by brief office-based cognitive screens (MMSE, MoCA) — these are insufficient for differential diagnosis or treatment planning.
• Cite AAN practice guidelines for the specific indication.

Stroke Rehabilitation

Post-stroke rehabilitation — including inpatient rehabilitation facility (IRF) stays, outpatient PT/OT/speech therapy, and cognitive rehabilitation — is frequently limited or denied. Document the patient's functional deficits (FIM scores, functional assessment), the intensity of rehabilitation required, and the clinical expectation of functional improvement. Medicare and commercial plans both require documentation of "reasonable expectation of improvement" for ongoing skilled therapy.

Building a Strong Neurology Appeal

Regardless of the specific condition, strong neurology appeals share these elements:

1. Neurologist letter of medical necessity — written by the treating specialist, citing specific clinical findings, diagnostic test results (MRI, EEG, neuropsychological testing), and relevant guideline citations (AAN, AHS)

2. Objective clinical data — MRI reports, EEG results, headache diaries, relapse records, cognitive test scores, functional assessments (FIM, Expanded Disability Status Scale for MS)

3. Step therapy documentation — complete timeline of previously tried and failed therapies with doses, durations, and outcomes

4. Guideline citations — AAN Clinical Practice Guidelines are peer-reviewed, evidence-based, and widely accepted as the standard of care for neurology conditions

5. Peer-to-peer review — neurology denials often turn on specialist judgment; request that your neurologist speak directly with the insurer's medical director

Resources

• American Academy of Neurology (AAN) (aan.com) — clinical practice guidelines, patient advocacy resources
• National MS Society (nationalmssociety.org) — insurance navigation, free MS Navigator service
• American Migraine Foundation — insurance toolkit for CGRP inhibitor appeals
• Manufacturer assistance programs — Novartis (Aimovig), Teva (Ajovy), Eli Lilly (Emgality), Genentech (Ocrevus), Biogen (Tysabri), and others all have patient support programs

Neurology denials are common, but with specialist documentation and guideline citations, they are frequently overturned on appeal.

Fight Back With ClaimBack

ClaimBack's free AI tool drafts a professional appeal letter in minutes, tailored to your insurer and denial reason. Don't let a denial be the final word. Fight your denial at ClaimBack →

Related Reading:

• How to Write an Insurance Appeal Letter
• What Is Medical Necessity?
• What Is Step Therapy?